CNRM and DSG Battle US Troops' Traumatic Brain Injury
The Center for Neuroscience and Regenerative Medicine (CNRM) is using DSG’s eCaseLink™ EDC (electronic data capture) system in three key studies on traumatic brain injury (TBI) in an effort to properly classify, diagnose, and combat one of the leading medical issues for US military troops and veterans.
DSG’s eCaseLink system captures study data electronically at the point of research, making data collection highly efficient. At any time throughout the study, clean, accurate data is available for review. This gives researchers a direct and immediate way to gather new insights about TBI and about the studies themselves. eCaseLink accelerates the TBI study process by streamlining data collection, bringing new understanding and potential treatments to the troops faster and safer.
Two of the current studies are exploring new methods of diagnosing TBI. Building on the success of previous research concerning similar conditions, the studies are using MR (magnetic resonance) imaging rather than standard CT (computer tomography) scans because of the MRI’s ability to show the location and severity of injury, and potentially predict outcomes.
In the third study, daily exercise and bright light therapy (BLT) are used for physical, cognitive, and mood stimulation. A series of assessments then gauge progress by comparing results to those of healthy patients.
Traumatic brain injury is a growing concern for the US military, especially since Operation Iraqi Freedom and Operation Iraqi Endurance were launched. As of March 2010, nearly 144,000 cases of TBI have been reported. Of that total, roughly 77% were classified as mild TBI—which often goes untreated but still leads to cognitive, behavioral, and communicative problems—resulting in a lower quality of life.
Several military and government organizations have come together to address the magnitude of TBI’s impact and how little is known about the condition.
“DSG is proud to play a critical role in the understanding and treatment of TBI for US combat troops and veterans,” said Tony Varano, CEO of DSG, Inc. “As a former Marine, it’s a distinct honor to work closely with CNRM to explore treatments for our brave soldiers.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
